Product logins

Find logins to all Clarivate products below.


Retinal Vein Occlusion – Epidemiology – Epidemiology Dashboard

Clarivate’s Epidemiology’s coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations. We report the prevalence of retinal vein occlusion for each country as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of ten years for the other countries covered in this report. For the mature markets, the patient population is forecast over a period of 20 years.

Clarivate Epidemiology’s retinal vein occlusion forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of retinal vein occlusion over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year,Clarivate’s Epidemiology provides at least ten years of forecast data for the following retinal vein occlusion subpopulations:

  • Total prevalent RVO cases by subtype scheme.
  • Total prevalent RVO cases with comorbid macular edema.

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…